Abstract: A method for enhancing an expression of insulin like growth factor 1 receptor in an umbilical cord mesenchymal stem cell is provided. The method includes culturing the umbilical cord mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the umbilical cord mesenchymal stem cell.

Abstract: A method for enhancing an expression of insulin like growth factor 1 receptor in a mesenchymal stem cell is provided. The method includes culturing the mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the mesenchymal stem cell.

Abstract: The present disclosure provides an engineered stem cell, comprising a vector comprising a polynucleotide comprising a nucleic acid sequence of suicide gene, a nucleic acid sequence of immune checkpoint gene and a natural cytotoxicity triggering receptor or a TNF-related apoptosis-inducing ligand, wherein the stem cell is a tumor-targeting cell. The present disclosure also provides a method for treating a cancer or enhancing intratumor immunity or enhancing immunity in tumor microenvironment in a subject, comprising administering an effective amount of the engineered stem cell of the present disclosure to the subject.

Abstract: A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.

Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.

Abstract: A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).

Abstract: A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).

Abstract: A method for enhancing an expression of insulin like growth factor 1 receptor in a mesenchymal stem cell is provided. The method includes culturing the mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the mesenchymal stem cell.

Abstract: A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

Abstract: A method for enhancing an insulin like growth factor 1 receptor expression of a mesenchymal stem cell is provided. The method includes culturing a plurality of mesenchymal stem cells expressing insulin-like growth factor 1 receptors in media containing human cord blood serum to enhance the insulin like growth factor 1 receptor expression of the mesenchymal stem cells.

Abstract: A kit for detecting urothelial carcinoma is provided. The kit includes at least one primer or probe for detecting one or more miRNAs, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof. A method for detecting urothelial carcinoma is also provided. The method includes detecting the expression level(s) of one or more miRNAs in a sample of a subject, and the one or more miRNAs are selected from the group consisting of miR-19b-1, miR-636, miR-150, miR-155, miR-183, miR-378, miR-210, miR-487, and combinations thereof.

Abstract: The present disclosure provides an engineered stem cell, comprising a vector comprising a polynucleotide comprising a nucleic acid sequence of suicide gene, a nucleic acid sequence of immune checkpoint gene and a natural cytotoxicity triggering receptor or a TNF-related apoptosis-inducing ligand, wherein the stem cell is a tumor-targeting cell. The present disclosure also provides a method for treating a cancer or enhancing intratumor immunity or enhancing immunity in tumor microenvironment in a subject, comprising administering an effective amount of the engineered stem cell of the present disclosure to the subject.

Abstract: A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.

Abstract: The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

Abstract: A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

Abstract: A method for enhancing an insulin like growth factor 1 receptor expression of a mesenchymal stem cell is provided. The method includes culturing a plurality of mesenchymal stem cells expressing insulin-like growth factor 1 receptors in media containing human cord blood serum to enhance the insulin like growth factor 1 receptor expression of the mesenchymal stem cells.

Abstract: The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

Abstract: The invention provides a M.2 interface memory device and a M.2 interface connection seat insertedly provided thereof. The M.2 interface memory device comprises a M.2 interface card and a housing provided with at least one guide groove. The M.2 interface connection seat is disposed on a circuit board, and comprises two arms and a base comprising a M.2 interface slot. At least one arm is provided with a guide rail. An opening direction of the M.2 interface slot is horizontal to a surface of the circuit board. When the M.2 interface card is inserted into the M.2 interface slot in a horizontal direction, the M.2 interface memory device will be fixed within the M.2 interface connection seat by embedding between the guide groove and the guide rail. Thus, M.2 interface memory devices of a variety of specification lengths are able to be inserted into the M.2 interface connection seat.

Abstract: The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

Abstract: The invention provides a M.2 interface memory device and a M.2 interface connection seat insertedly provided thereof. The M.2 interface memory device comprises a M.2 interface card and a housing provided with at least one guide groove. The M.2 interface connection seat is disposed on a circuit board, and comprises two arms and a base comprising a M.2 interface slot. At least one arm is provided with a guide rail. An opening direction of the M.2 interface slot is horizontal to a surface of the circuit board. When the M.2 interface card is inserted into the M.2 interface slot in a horizontal direction, the M.2 interface memory device will be fixed within the M.2 interface connection seat by embedding between the guide groove and the guide rail. Thus, M.2 interface memory devices of a variety of specification lengths are able to be inserted into the M.2 interface connection seat.